JP2023542724A - 造血前駆細胞キナーゼ１（ｈｐｋ１）阻害剤としてのインダゾールおよびその使用方法 - Google Patents
造血前駆細胞キナーゼ１（ｈｐｋ１）阻害剤としてのインダゾールおよびその使用方法 Download PDFInfo
- Publication number
- JP2023542724A JP2023542724A JP2023519504A JP2023519504A JP2023542724A JP 2023542724 A JP2023542724 A JP 2023542724A JP 2023519504 A JP2023519504 A JP 2023519504A JP 2023519504 A JP2023519504 A JP 2023519504A JP 2023542724 A JP2023542724 A JP 2023542724A
- Authority
- JP
- Japan
- Prior art keywords
- fluoro
- indazol
- carboxamide
- imidazo
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
- C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063084059P | 2020-09-28 | 2020-09-28 | |
| US63/084,059 | 2020-09-28 | ||
| PCT/IB2021/058794 WO2022064458A1 (en) | 2020-09-28 | 2021-09-27 | Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023542724A true JP2023542724A (ja) | 2023-10-11 |
| JP2023542724A5 JP2023542724A5 (https=) | 2024-10-07 |
Family
ID=80821021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023519504A Pending JP2023542724A (ja) | 2020-09-28 | 2021-09-27 | 造血前駆細胞キナーゼ１（ｈｐｋ１）阻害剤としてのインダゾールおよびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11834467B2 (https=) |
| EP (1) | EP4217358A4 (https=) |
| JP (1) | JP2023542724A (https=) |
| KR (1) | KR20230104143A (https=) |
| CN (2) | CN114599651B (https=) |
| AU (1) | AU2021347913A1 (https=) |
| CA (1) | CA3193865A1 (https=) |
| IL (1) | IL301244A (https=) |
| MX (1) | MX2023003631A (https=) |
| TW (1) | TWI908894B (https=) |
| WO (2) | WO2022064459A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022064459A1 (en) * | 2020-09-28 | 2022-03-31 | 1ST Biotherapeutics, Inc. | Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same |
| EP4499643A4 (en) * | 2022-03-25 | 2026-01-28 | 1St Biotherapeutics Inc | INDAZOLES USED AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND THEIR METHODS OF USE |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009530233A (ja) * | 2006-02-14 | 2009-08-27 | ノバルティス アーゲー | Ｐｉ−３キナーゼインヒビターおよびそれらの使用方法 |
| WO2012052745A1 (en) * | 2010-10-21 | 2012-04-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Combinations of pi3k inhibitors with a second anti -tumor agent |
| JP2018510192A (ja) * | 2015-04-02 | 2018-04-12 | セロン ファーマ エス．アー．Ｃｅｌｏｎ Ｐｈａｒｍａ Ｓ．Ａ． | 免疫もしくは炎症性の疾患またはがんの処置に有用な７−（モルホリン−４−イル）ピラゾール［１，５−ａ］ピリミジン誘導体 |
| WO2020170206A1 (en) * | 2019-02-22 | 2020-08-27 | 1ST Biotherapeutics, Inc. | Imidazopyridinyl compounds and use thereof for treatment of proliferative disorders |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200911798A (en) | 2007-08-02 | 2009-03-16 | Amgen Inc | PI3 kinase modulators and methods of use |
| US8993580B2 (en) * | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| WO2010008847A2 (en) | 2008-06-24 | 2010-01-21 | Takeda Pharmaceutical Company Limited | Pi3k/m tor inhibitors |
| US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
| PL2716157T3 (pl) | 2008-12-08 | 2017-06-30 | Gilead Connecticut, Inc. | Imidazopirazynowe inhibitory Syk |
| WO2010100144A1 (en) * | 2009-03-04 | 2010-09-10 | Merck Serono S.A. | Fused bicyclic compounds as inhibitors for pi3 kinase |
| BRPI1014572B8 (pt) | 2009-04-16 | 2022-07-19 | Fundacion Centro Nac De Investigaciones Oncologicas Carlos Iii | Imidazopirazinas para uso como inibidores de cinase |
| US9073927B2 (en) | 2010-01-22 | 2015-07-07 | Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii | Inhibitors of PI3 kinase |
| AR086042A1 (es) | 2011-04-28 | 2013-11-13 | Galapagos Nv | Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica |
| WO2013130855A1 (en) | 2012-03-02 | 2013-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
| MA42456B1 (fr) * | 2015-06-25 | 2021-06-30 | Univ Health Network | Inhibiteurs de hpk1 et leurs procédés d'utilisation |
| CN115819417A (zh) * | 2016-09-09 | 2023-03-21 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途 |
| AU2018244935A1 (en) * | 2017-03-30 | 2019-08-15 | F. Hoffmann-La Roche Ag | Naphthyridines as inhibitors of HPK1 |
| AU2018346051B2 (en) | 2017-10-02 | 2022-11-10 | 1st Biotherapeutics Inc. | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders |
| CN109721620B (zh) * | 2017-10-27 | 2022-05-13 | 药捷安康(南京)科技股份有限公司 | Hpk1抑制剂及其用途 |
| EP3707138B1 (en) * | 2017-11-06 | 2022-07-13 | Bristol-Myers Squibb Company | Isofuranone compounds useful as hpk1 inhibitors |
| EP3877371A4 (en) * | 2018-11-07 | 2022-07-27 | Dana-Farber Cancer Institute, Inc. | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF |
| WO2022064459A1 (en) * | 2020-09-28 | 2022-03-31 | 1ST Biotherapeutics, Inc. | Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same |
-
2021
- 2021-09-27 WO PCT/IB2021/058795 patent/WO2022064459A1/en not_active Ceased
- 2021-09-27 AU AU2021347913A patent/AU2021347913A1/en active Pending
- 2021-09-27 JP JP2023519504A patent/JP2023542724A/ja active Pending
- 2021-09-27 TW TW110135855A patent/TWI908894B/zh active
- 2021-09-27 MX MX2023003631A patent/MX2023003631A/es unknown
- 2021-09-27 EP EP21871811.2A patent/EP4217358A4/en active Pending
- 2021-09-27 US US17/485,653 patent/US11834467B2/en active Active
- 2021-09-27 CN CN202180003282.9A patent/CN114599651B/zh active Active
- 2021-09-27 IL IL301244A patent/IL301244A/en unknown
- 2021-09-27 KR KR1020237014773A patent/KR20230104143A/ko active Pending
- 2021-09-27 US US17/485,711 patent/US11649255B2/en active Active
- 2021-09-27 WO PCT/IB2021/058794 patent/WO2022064458A1/en not_active Ceased
- 2021-09-27 CN CN202180003294.1A patent/CN114599653B/zh active Active
- 2021-09-27 CA CA3193865A patent/CA3193865A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009530233A (ja) * | 2006-02-14 | 2009-08-27 | ノバルティス アーゲー | Ｐｉ−３キナーゼインヒビターおよびそれらの使用方法 |
| WO2012052745A1 (en) * | 2010-10-21 | 2012-04-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Combinations of pi3k inhibitors with a second anti -tumor agent |
| JP2018510192A (ja) * | 2015-04-02 | 2018-04-12 | セロン ファーマ エス．アー．Ｃｅｌｏｎ Ｐｈａｒｍａ Ｓ．Ａ． | 免疫もしくは炎症性の疾患またはがんの処置に有用な７−（モルホリン−４−イル）ピラゾール［１，５−ａ］ピリミジン誘導体 |
| WO2020170206A1 (en) * | 2019-02-22 | 2020-08-27 | 1ST Biotherapeutics, Inc. | Imidazopyridinyl compounds and use thereof for treatment of proliferative disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| US11834467B2 (en) | 2023-12-05 |
| TWI908894B (zh) | 2025-12-21 |
| AU2021347913A1 (en) | 2023-05-18 |
| CN114599653A (zh) | 2022-06-07 |
| CN114599653B (zh) | 2025-12-16 |
| IL301244A (en) | 2023-05-01 |
| CN114599651B (zh) | 2025-12-16 |
| MX2023003631A (es) | 2023-04-11 |
| CN114599651A (zh) | 2022-06-07 |
| US20220098219A1 (en) | 2022-03-31 |
| US20220098193A1 (en) | 2022-03-31 |
| EP4217358A1 (en) | 2023-08-02 |
| TW202220999A (zh) | 2022-06-01 |
| US11649255B2 (en) | 2023-05-16 |
| KR20230104143A (ko) | 2023-07-07 |
| EP4217358A4 (en) | 2025-01-08 |
| WO2022064459A1 (en) | 2022-03-31 |
| CA3193865A1 (en) | 2022-03-31 |
| AU2021347913A9 (en) | 2024-06-27 |
| WO2022064458A1 (en) | 2022-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102376354B1 (ko) | 6-(5-히드록시-1h-피라졸-1-일)니코틴아미드 유도체 및 ｐｈｄ의 저해제로서의 그의 용도 | |
| AU2014364744B2 (en) | Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments | |
| JP6609631B2 (ja) | 縮合環ヘテロアリール化合物及びｔｒｋ抑制剤としての用途 | |
| AU2016366546B2 (en) | Inhibitors of Bruton's tyrosine kinase and methods of their use | |
| UA81994C2 (en) | 5,7-diaminopyrazolo [4,3-d] pyrimidines with pde-5 inhibiting activity | |
| BR112015009168B1 (pt) | Composto de fórmula estrutural xi ou um sal do mesmo, uso de um composto e composição farmacêutica | |
| JP2016512816A (ja) | Ａｔｒキナーゼの阻害剤として有用な化合物 | |
| EP2976341A1 (en) | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors | |
| AU2014234908A1 (en) | N-(2-cyano heterocyclyl)pyrazolo pyridones as Janus kinase inhibitors | |
| JP2023542724A (ja) | 造血前駆細胞キナーゼ１（ｈｐｋ１）阻害剤としてのインダゾールおよびその使用方法 | |
| IL323451A (en) | The history of modified thiophene compounds, the compositions containing them, and their use as medicines | |
| JP2008517994A (ja) | 新規医薬品 | |
| RU2854594C1 (ru) | Индазолы в качестве ингибиторов киназы 1 гемопоэтического предшественника (hpk1) и способы их применения | |
| CN119212997A (zh) | 作为造血祖细胞激酶1（hpk1）抑制剂的吲唑及其使用方法 | |
| TW202430512A (zh) | 類木瓜蛋白酶(PLpro)抑制劑 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240927 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240927 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250814 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250902 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251118 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260210 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260326 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260414 |